Monday 12 May, 2025 04:17 PM
Site map | Locate Us | Login
   Man Industries hits the roof after PAT rises nearly 3x YoY to Rs 68 crore in Q4    Piramal Pharma gains after receiving EIR for Turbhe facility from USFDA    Wanbury spurts after Tanuku facility clears ANVISA inspection with zero observations    K P R Mill Ltd leads losers in 'A' group    Bajaj Electricals soars after strong Q4 performance    Dr Reddys Lab jumps after Q4 PAT rises 22% YoY    Venkys (India) slides after Q4 PAT tumble 60% YoY to Rs 13 cr    Premier Explosives Ltd leads losers in 'B' group    TFCI jumps after Q4 PAT rises 48% YoY to Rs 30 cr    Volumes soar at C.E. Info Systems Ltd counter    TCS soars after signing digital transformation pact with Oman's largest insurer Dhofar Insurance    Yes Bank gains as Japan's SMBC to acquire 20% stake in landmark deal    Sun Pharmaceutical Industries Ltd eases for fifth straight session    Castrol India Ltd soars 1.91%, rises for third straight session    Nazara Technologies Ltd spurts 4.73%, gains for five straight sessions 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Unichem Lab net loss widens to Rs 129 cr in Q4
22-May-24   15:30 Hrs IST

Revenue from operations rose 7.36% year on year (YoY) to Rs 431.70 crore in the quarter ended 31 March 2024.

The drug maker recorded loss before exceptional item and tax of Rs 0.25 crore in Q4 FY24 as compared with loss before exceptional item and tax of Rs 13.61 crore in Q4 FY23.

The company has a provision for European commission fine as exceptional loss stood of Rs 125.62 crore in the March 2024 quarter. The exceptional loss stood at Rs 33.54 crore in Q4 FY23, due to one-time discretionary loyalty bonus.

On a full year basis, the firm posted consolidated net loss of Rs 70.47 crore in FY24 as against net loss of Rs 202.23 crore in FY23. Net sales rose 26.94% YoY to Rs 1,442.16 crore in financial year ended March 2024.

Unichem Laboratories is a pharmaceutical company. It addresses the needs of therapeutic areas like gastroenterology, cardiology, diabetology, psychiatry, neurology, anti-bacterials, anti-infectives and pain management.

The scrip rose 0.10% to close at Rs 561.55 on the BSE.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.R Udayakumar , compliance@ssplwealth.com,  Mobile No: 7305522205
Hit Count : 40797268
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 56990 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. SSPL WEALTH Pvt. Ltd